GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » Cyclically Adjusted PB Ratio

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Cyclically Adjusted PB Ratio : (As of Jun. 22, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cotinga Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Cotinga Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cotinga Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Cotinga Pharmaceuticals Annual Data
Trend Apr10 Apr11 Apr12 Apr13 Apr14 Apr15 Apr16 Apr17 Apr18 Apr19
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cotinga Pharmaceuticals Quarterly Data
Apr15 Jul15 Oct15 Jan16 Apr16 Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cotinga Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Cotinga Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cotinga Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cotinga Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cotinga Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Cotinga Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Cotinga Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jan. 2020 is calculated as:

For example, Cotinga Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jan. 2020 was:

Adj_Book=Book Value per Share/CPI of Jan. 2020 (Change)*Current CPI (Jan. 2020)
=-0.136/108.0853*108.0853
=-0.136

Current CPI (Jan. 2020) = 108.0853.

Cotinga Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201004 0.898 91.651 1.059
201007 0.752 92.283 0.881
201010 0.686 92.757 0.799
201101 0.589 93.074 0.684
201104 0.730 94.654 0.834
201107 0.633 94.812 0.722
201110 0.520 95.444 0.589
201201 0.439 95.365 0.498
201204 0.515 96.550 0.577
201207 0.414 95.997 0.466
201210 0.334 96.550 0.374
201301 0.295 95.839 0.333
201304 0.236 96.945 0.263
201307 0.221 97.261 0.246
201310 0.258 97.182 0.287
201401 0.184 97.261 0.204
201404 0.141 98.920 0.154
201407 0.158 99.315 0.172
201410 0.127 99.473 0.138
201501 0.213 98.209 0.234
201504 0.105 99.710 0.114
201507 0.170 100.579 0.183
201510 0.128 100.500 0.138
201601 0.119 100.184 0.128
201604 0.214 101.370 0.228
201607 0.173 101.844 0.184
201610 0.154 102.002 0.163
201701 0.110 102.318 0.116
201704 0.030 103.029 0.031
201707 0.031 103.029 0.033
201710 0.042 103.424 0.044
201801 -0.012 104.056 -0.012
201804 -0.074 105.320 -0.076
201807 -0.027 106.110 -0.028
201810 -0.042 105.952 -0.043
201901 -0.050 105.557 -0.051
201904 -0.082 107.453 -0.082
201907 -0.098 108.243 -0.098
201910 -0.116 107.927 -0.116
202001 -0.136 108.085 -0.136

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cotinga Pharmaceuticals  (OTCPK:COTQF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Cotinga Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1
Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Headlines

From GuruFocus

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire 05-22-2019